JPMorgan Chase & Co. Issues Pessimistic Forecast for Incyte (NASDAQ:INCY) Stock Price
Incyte (NASDAQ:INCY – Get Free Report) had its price target lowered by analysts at JPMorgan Chase & Co. from $70.00 to $68.00 in a research note issued to investors on Monday,Benzinga reports. The firm currently has a “neutral” rating on the biopharmaceutical company’s stock. JPMorgan Chase & Co.‘s price objective indicates a potential upside of […]
Incyte (NASDAQ:INCY – Get Free Report) had its price target lowered by analysts at JPMorgan Chase & Co. from $70.00 to $68.00 in a research note issued to investors on Monday,Benzinga reports. The firm currently has a “neutral” rating on the biopharmaceutical company’s stock. JPMorgan Chase & Co.‘s price objective indicates a potential upside of […]